Ashley Moyer, APRN
Adult Health · Bentonville, ARNPI 1215386065
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,619, 2.1 times the $782 reported in 2021. Among adult health clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $36.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$984
- Novo Nordisk$692
- AbbVie$472
- Inari Medical, Inc.$264
- Amgen$222
- Astellas Pharma US Inc$206
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,07896%
- Education$1854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $984 |
| Novo Nordisk | 16 | $692 |
| AbbVie | 14 | $472 |
| Inari Medical, Inc. | 2 | $264 |
| Amgen | 7 | $222 |
| Astellas Pharma US Inc | 3 | $206 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $152 |
| GSK | 6 | $143 |
| Otsuka America Pharmaceutical, Inc. | 2 | $122 |
| Gilead | 2 | $121 |
| Intuitive Surgical | 1 | $108 |
| Bayer | 5 | $91 |
| Esperion Therapeutics, Inc. | 1 | $88 |
| Dexcom, Inc. | 4 | $82 |
| Viiv Healthcare Company | 1 | $80 |
| Vanda Pharmaceuticals Inc. | 2 | $65 |
| Sumitomo Pharma America, Inc. | 3 | $55 |
| Boehringer Ingelheim | 3 | $54 |
| Pfizer | 3 | $53 |
| Collegium Pharmaceutical, Inc. | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Corium, LLC | 1 | $28 |
| Lundbeck LLC | 1 | $27 |
| Solventum Corporation | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$375
- Ozempic$246
- FLOWTRIEVER CATHETER, S$166
- CT THROMBECTOMY SYSTEM KIT$166
- RYBELSUS$125
- Creon$125
- BREZTRI$122
- QULIPTA$121
- Da Vinci Surgical System$108
- Epclusa$100
How this compares
$4,263 in reported general payments places this provider in the 90th percentile of 154 adult health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 147 | $188,620 |
| EliquisApixaban | 101 | $95,415 |
| OzempicSemaglutide | 63 | $88,984 |
| MyrbetriqMirabegron | 78 | $66,772 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $57,659 |
| FarxigaDapagliflozin Propanediol | 53 | $53,919 |
| TrulicityDulaglutide | 36 | $46,725 |
| JardianceEmpagliflozin | 26 | $30,177 |
| JanuviaSitagliptin Phosphate | 22 | $26,604 |
| XareltoRivaroxaban | 16 | $25,462 |
| LinzessLinaclotide | 33 | $23,301 |
| Repatha SureclickEvolocumab | 11 | $18,086 |
| RexultiBrexpiprazole | 12 | $17,703 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $16,963 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $11,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $15 | $235,345183 claims |
| PfizerEliquis, Paxlovid | $53 | $99,563145 claims |
| Novo NordiskOzempic | $692 | $88,98463 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere, Symbicort | $984 | $78,05094 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $143 | $69,22088 claims |
| Astellas Pharma US IncMyrbetriq | $206 | $66,77278 claims |
| Boehringer IngelheimJardiance | $54 | $30,17726 claims |
| AbbVieLinzess | $472 | $23,30133 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $122 | $17,70312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 154 adult health providers in Arkansas.
Other adult health in Bentonville
- Darren CompasBentonville$8K
- Holly MooreLittle Rock$59K
- Deborah ShipmanJonesboro$41K
- Lisa HurdJonesboro$12K
- Kari SchrankFayetteville$9K
- Amanda McClureFayetteville$9K
- Gina NullFort Smith$8K
- Lisa HarveyHot Springs$8K
- Abby MartensSpringdale$7K
- Marie JonesFayetteville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.